- Little Green Pharma (LGP) is set to supply and fund a study examining the changes in quality-of-life for patients prescribed medicinal cannabis
- The ASX-lister has been exclusively appointed to supply and fund the quality of life evaluation study (QUEST) as well as providing administration and technical advice on its products
- Headed up by researchers at the University of Sydney, the two year study could potentially become one of the world’s largest in its kind
- The study is currently open and planned to close in March 2022
- Little Green Pharma shares closed the session up 3.68 per cent at 70.5 cents each
Little Green Pharma (LGP) is set to supply and fund a study examining the changes in quality-of-life for patients prescribed medicinal cannabis.
The ASX-lister has been exclusively appointed to supply medicinal cannabis oil products to enrolled patients in addition well as providing funding for study costs.
The company will also provide technical advice on its products and their administration, which was incorporated into the study design.
The quality of life evaluation study, conducted by researchers at the University of Sydney, will take place over two years and will look to recruit at lest 2100 patients by the end of June.
There is also potential to take the study internationally.
More broadly, the QUEST Initiative is tipped to be one of the world’s largest
longitudinal studies investigating the quality of life and health economics on patients with chronic disease prescribed medicinal cannabis.
During the study, patients changes and conditions will be self-reported using quality-of-life outcomes, such as patient mobility, functionality, pain or discomfort, anxiety and depression.
The study is currently open and planned to close in March 2022.
Little Green Pharma shares closed the session up 3.68 per cent at 70.5 cents each.